PDE5A and hyperthyroidism: The goal of the current study was to test the hypothesis that multikinase inhibitor, sorafenib, PDE-5 inhibitor, tadalafil, and dual endothelin-1 receptor blocker, macitentan, could be potential therapies for cardiac remodeling, RV contractile abnormalities and/or LV systolic dysfunction in experimental hyperthyroidism.